QSAM Biosciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended
Jun. 30, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 9 – SUBSEQUENT EVENTS On July 26, 2023, the Board approved amendments to the employment agreements of the Company’s EVP/General Counsel and its VP-Operations, to increase the contingent compensation Transaction Bonus for both employees to 1% of the Net Proceeds received by the Company from a Major Transaction, as such terms are defined in their respective agreements. On July 27, 2023, the Company issued 16,000 shares to a service provider as the second tranche of compensation pursuant to an agreement signed in April 2023. On August 11, 2023, the Company issued 30,000 shares to a second service provider pursuant to an agreement signed in April 2023.

SUBSEQUENT EVENTS

6 Months Ended

Jun. 30, 2023

NOTE 9 – SUBSEQUENT EVENTS

On July 26, 2023, the Board approved amendments to the employment agreements of the Company’s EVP/General Counsel and its VP-Operations, to increase the contingent compensation Transaction Bonus for both employees to 1% of the Net Proceeds received by the Company from a Major Transaction, as such terms are defined in their respective agreements.

On July 27, 2023, the Company issued 16,000 shares to a service provider as the second tranche of compensation pursuant to an agreement signed in April 2023. On August 11, 2023, the Company issued 30,000 shares to a second service provider pursuant to an agreement signed in April 2023.